Page 613«..1020..612613614615..»

Dyadic in deal to license biotechnology – Bizjournals.com

By Dr. Matthew Watson


Bizjournals.com
Dyadic in deal to license biotechnology
Bizjournals.com
Emalfarb said he's working on a final license agreement with EnGen Bio, which is led by Mark R. Alfenito, a biotechnology veteran who has completed more ...
Dyadic International Signs Term Sheet for Potential Exclusive Outlicense of C1 ...PR Newswire (press release)

all 11 news articles »

To Read More: Dyadic in deal to license biotechnology – Bizjournals.com
categoriaUncategorized commentoComments Off on Dyadic in deal to license biotechnology – Bizjournals.com | dataJune 10th, 2010
Read All

International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss ‘Status of the Company’

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCO), a California-based biotechnology company creating human stem cell lines through its patented parthenogenetic process that requires no use of fertilized embryos, today announced that it is has scheduled a conference call for June 15, 2010 at 10:00 a.m. PST. ISCO Chairman, Mr. Kenneth Aldrich will discuss the Company's newly issued patent, its recently completed financing, and the present status of the company and its vision for the coming year. The dial-in number for participants is 1 (800) 774-6070 and the pass code ID is 8273 225#. An alternate dial-in number is: 1 (630) 691-2753 and the pass code will be the same for both numbers. A replay of the call will be available on the home page of the company's web site at: http://www.internationalstemcell.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells (hpSCs) from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCellTM, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS:

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

To Read More: International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss ‘Status of the Company’
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss ‘Status of the Company’ | dataJune 10th, 2010
Read All

Genzyme fends off looming proxy fight – Boston Globe

By Dr. Matthew Watson


Boston Globe
Genzyme fends off looming proxy fight
Boston Globe
Activist shareholder Carl C. Icahn has completed deals with two big Cambridge biotechnology companies — Biogen Idec and Genzyme. ...
Genzyme, Icahn reach accord, ending proxy fightReuters (press release)
Genzyme and Carl Icahn Reach AgreementMarketWatch (press release)
Icahn withdraws Genzyme board nomineesFinancial Times
Wall Street Journal -BusinessWeek -The Associated Press
all 180 news articles »

To Read More: Genzyme fends off looming proxy fight – Boston Globe
categoriaUncategorized commentoComments Off on Genzyme fends off looming proxy fight – Boston Globe | dataJune 10th, 2010
Read All

‘Splice’ Is A Stylish, Scary Movie – Arizona Reporter

By Dr. Matthew Watson


ABC News
'Splice' Is A Stylish, Scary Movie
Arizona Reporter
Genetic engineering is at the forefront of science these days, so it's not surprising that brilliant biochemists Clive (Adrien Brody) and Elsa (Sarah ...
AT THE MOVIES|SpliceKawartha Media Group
Playing The Genetics Game With "Splice"RTT News

all 64 news articles »

To Read More: ‘Splice’ Is A Stylish, Scary Movie – Arizona Reporter
categoriaUncategorized commentoComments Off on ‘Splice’ Is A Stylish, Scary Movie – Arizona Reporter | dataJune 9th, 2010
Read All

Genetically Engineered Trees Coming To Georgia – GPB

By Dr. Matthew Watson


Washington Post
Genetically Engineered Trees Coming To Georgia
GPB
South Carolina based ArborGen uses genetic engineering to grow more trees. They received USDA approval to plant 28 plots of their ...
Paper industry tests genetically altered treesThe Associated Press
Paper Industry Eyes Genetically Engineered Eucalyptus to Conserve ForestsTreehugger

all 308 news articles »

To Read More: Genetically Engineered Trees Coming To Georgia – GPB
categoriaUncategorized commentoComments Off on Genetically Engineered Trees Coming To Georgia – GPB | dataJune 9th, 2010
Read All

Anger grows at restrive biotechnology patents – Adelaidenow

By Dr. Matthew Watson


ABC Online
Anger grows at restrive biotechnology patents
Adelaidenow
BIOTECHNOLOGY companies that have patented human genes are monopolising the market, stifling important research and stopping patients getting crucial tests, ...
Cancer gene case spooks biotech companiesABC Online
BRCA1 gene patent challenged in Australian courtAustralian Life Scientist
Should Companies Be Allowed To Patent Breast Cancer Gene?Politics Daily (blog)
Sydney Morning Herald
all 25 news articles »

To Read More: Anger grows at restrive biotechnology patents – Adelaidenow
categoriaUncategorized commentoComments Off on Anger grows at restrive biotechnology patents – Adelaidenow | dataJune 9th, 2010
Read All

International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCO), http://www.intlstemcell.com, announced today that the United States Patent and Trademark Office (USPTO) has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells (hpSC). Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

Although ISCO's creation of human parthenogenetic stem cells was first announced in a peer review publication in 2007, the formal allowance of claims by the USPTO will greatly advance the field of regenerative medicine by allowing ISCO to share its knowledge of these hpSC lines more freely with researchers in the US and around the world through partnerships, joint ventures, funded research and licensing arrangements.

The patent protects ISCO's technology platform, allowing the creation of hpSC from unfertilized eggs, exhibiting similar qualities and pluripotency as embryonic stem cells, with the added ability to be immune-matched to the donor, as illustrated in published peer-reviewed articles. Additional discoveries, also previously published in a peer reviewed journal and the subject of pending ISCO patents, illustrate the creation of 'homozygous' hpSC that can be immune matched to millions of persons of differing sexes and racial backgrounds, rather than only to the donor or her family, raising the potential of eventually creating a universal source of stem cells that could benefit most the of the world's population.

Researchers across the world work with ISCO to study different therapeutic applications of hpSC. Through previously announced collaborative arrangements, ISCO's scientists are working with major universities and private research organizations to study hpSC to treat liver disease, diabetes, Age-related Macular Degeneration (AMD), corneal blindness and various neural degenerative diseases. In one such research collaboration, internationally-recognized stem cell researcher Hans Keirstead, PhD, at the Reeve-Irvine Research Center (University of California, Irvine), recently published a paper, referring to his use of embryonic stem cells and ISCO's hpSC in work focused on the derivation of early retinal progenitor tissue.

Andrey Semechkin, PhD, CEO of ISCO said, 'Other than parthenogenetic stem cells, the three most commonly used and described types of stem cells are human embryonic stem cells (hESC), induced pluripotent stem cells (iPS), and adult stem cells, such as those derived from cord blood, adipose tissue or bone marrow. Parthenogenetic stem cells have unique advantages over each of these other cell types, and we anticipate that since our core patent has been issued, we can now accelerate the adoption of our hpSC lines by researchers in the US and throughout the world.'

'International Stem Cell Corporation is particularly proud of these accomplishments because we have been funded thus far entirely by investors, without NIH or other governmental aid,' said Jeffrey Janus, Senior Vice President of ISCO. 'However, once it is generally recognized that parthenogenetic cells have similar characteristics of embryonic stem cells and offer the potential to solve critical immune rejection issues - while not requiring the destruction of viable human embryos - we expect these cells to be increasingly used in government funded research to study ways of reducing human suffering and treating intractable human diseases.'

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell(TM), while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," " anticipates," "expects," "estimates,") should also be considered to be forward- looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

To Read More: International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office | dataJune 9th, 2010
Read All

Talecris agrees to $3.4 bln bid by Spain’s Grifols – MarketWatch

By Dr. Matthew Watson


RTT News
Talecris agrees to $3.4 bln bid by Spain's Grifols
MarketWatch
TEL AVIV (MarketWatch) -- Talecris Biotherapeutics (NASDAQ:TLCR) , the Research Triangle Park, NC, biotechnology firm, definitively agreed to be acquired by ...
Grifols To Pay $3.4 Bln In Cash, Shares For TalecrisWall Street Journal
WSJ: Spain's Grifols In Talks To Buy Talecris Biotherapeutics For About $3 Bln ...Daily Markets
Grifols to Acquire Talecris Biotherapeutics Creating a World Leading Provider ...PR Newswire (press release)

all 78 news articles »

To Read More: Talecris agrees to $3.4 bln bid by Spain’s Grifols – MarketWatch
categoriaUncategorized commentoComments Off on Talecris agrees to $3.4 bln bid by Spain’s Grifols – MarketWatch | dataJune 7th, 2010
Read All

How Real is the Science Behind ‘Splice’? – Wall Street Journal (blog)

By Dr. Matthew Watson


CBC.ca
How Real is the Science Behind 'Splice'?
Wall Street Journal (blog)
Many scientists and corporations are hailing recent breakthroughs in the field of biotechnology. Some research opponents, such as the Canada-based ETC Group ...
Movie Review: SpliceGeeks of Doom (blog)

all 40 news articles »

To Read More: How Real is the Science Behind ‘Splice’? – Wall Street Journal (blog)
categoriaUncategorized commentoComments Off on How Real is the Science Behind ‘Splice’? – Wall Street Journal (blog) | dataJune 6th, 2010
Read All

CSCs responsible for metastasis identified

By Dr. Matthew Watson

Cancer stem cells responsible for metastasis identified: HK study, Xinhua News Agency, June 4, 2010. Excerpt:

Hong Kong researchers have identified a subset of cancer stem cells responsible for metastasis in human colorectal cancer which can help better predict the prognosis and design a more suitable treatment for patients, according to a study made public by the University of Hong Kong on Friday.

The researchers from the university's medicine school discovered that cancer stem cells with a surface marker CD26, which marks a subset of cancer stem cells with metastatic capacity, are present in all terminal colon cancer cells and all metastatic cancer cells.

This news item is about the publication: A Subpopulation of CD26+ Cancer Stem Cells with Metastatic Capacity in Human Colorectal Cancer by Roberta Pang and 13 co-authors, including Wai Lun Law, Ronnie T Poon and Benjamin CY Wong [photos of authors], Cell Stem Cell 2010(Jun 4); 6(6): 603-15. [Summary][Twitter entry][Commentary][FriendFeed entry][Science Pond entry].

To Read More: CSCs responsible for metastasis identified
categoriaStem Cell Therapy commentoComments Off on CSCs responsible for metastasis identified | dataJune 6th, 2010
Read All

Out of Frame: Splice – DCist.com

By Dr. Matthew Watson


Globe and Mail
Out of Frame: Splice
DCist.com
Better living through genetic engineering takes a serious hit in Vincenzo Natali's Splice, a seriously creepy and surprisingly effective science-gone-awry ...
Splice (2008)New York Times
Splice ReviewHeavy.com (blog)
Roger Qbert Reviews “Splice”Review St. Louis (blog)
Television Without Pity -Seattle Times -The Catholic Spirit
all 707 news articles »

To Read More: Out of Frame: Splice – DCist.com
categoriaUncategorized commentoComments Off on Out of Frame: Splice – DCist.com | dataJune 4th, 2010
Read All

Exelixis signs financing deals worth $160 million – BusinessWeek

By Dr. Matthew Watson


RTT News
Exelixis signs financing deals worth $160 million
BusinessWeek
Biotechnology company Exelixis Inc. said Thursday it entered two financing deals for a combined $160 million. The company said it signed a deal with Silicon ...
Will Exelixis Hog Limelight At ASCO?RTT News
Exelixis to Raise $160 Million through Financing Transactions with Silicon ...MarketWatch (press release)

all 38 news articles »

To Read More: Exelixis signs financing deals worth $160 million – BusinessWeek
categoriaUncategorized commentoComments Off on Exelixis signs financing deals worth $160 million – BusinessWeek | dataJune 4th, 2010
Read All

Amgen Bets on Bone Drug to Revive Growth – Wall Street Journal

By Dr. Matthew Watson


The Money Times
Amgen Bets on Bone Drug to Revive Growth
Wall Street Journal
Amgen Inc. has become the biotechnology industry's most valuable company on the shoulders of drugs that strengthen the blood. ...
Options Brief: Amgen (AMGN) Calls Fly Following FDA ApprovalWall Street Pit (blog)
Ahead of the Bell: Amgen rises on Prolia approvalBusinessWeek
Another boost for Amgen as US FDA approves injectable osteoporosis drug Prolia ...The Pharma Letter
TopNews United Kingdom (blog) -Financial Times -Reuters
all 369 news articles »

To Read More: Amgen Bets on Bone Drug to Revive Growth – Wall Street Journal
categoriaUncategorized commentoComments Off on Amgen Bets on Bone Drug to Revive Growth – Wall Street Journal | dataJune 3rd, 2010
Read All

Splice (2008) – New York Times

By Dr. Matthew Watson


CBC.ca
Splice (2008)
New York Times
... horror movie about love and monsters in the age of genetic engineering, are Adrien Brody and Sarah Polley, a well-matched pair of earthbound oddities. ...
Movie review 'Splice': Thriller brings a human/animal hybrid to lifeSeattle Times
Catholic movie review - SpliceThe Catholic Spirit
Splice (2008)World Report Now (blog)
The Post-Standard - Syracuse.com -USA Today -San Francisco Chronicle
all 477 news articles »

To Read More: Splice (2008) – New York Times
categoriaUncategorized commentoComments Off on Splice (2008) – New York Times | dataJune 3rd, 2010
Read All

Momenta Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences … – MarketWatch (press release)

By Dr. Matthew Watson


Earthtimes (press release)
Momenta Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences ...
MarketWatch (press release)
Momenta Pharmaceuticals is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture ...
ISTO Technologies, Inc. to Present at the Jefferies 2010 Global Life Sciences ...TapeBeat

all 296 news articles »

To Read More: Momenta Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences … – MarketWatch (press release)
categoriaUncategorized commentoComments Off on Momenta Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences … – MarketWatch (press release) | dataJune 3rd, 2010
Read All

Chemist, biologist wins MIT inventor’s prize – Reuters

By Dr. Matthew Watson


Bradenton Herald
Chemist, biologist wins MIT inventor's prize
Reuters
BOSTON (Reuters) - A University of California chemistry and biology professor whose research is applied widely in biotechnology became on Wednesday the ...
Berkeley Professor Wins $500000 Prize for Work in BiotechnologyChronicle of Higher Education (subscription)
Biochemist wins $500000 Lemelson-MIT PrizeCNET
UC Berkeley Chemical Biologist Wins 'Oscar For Inventors'Inventorspot
Business Wire (press release)
all 42 news articles »

To Read More: Chemist, biologist wins MIT inventor’s prize – Reuters
categoriaUncategorized commentoComments Off on Chemist, biologist wins MIT inventor’s prize – Reuters | dataJune 3rd, 2010
Read All

Phase I clinical trial of ICT-107

By Dr. Matthew Watson

Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107) by Surasak Phuphanich and 9 co-authors, including Manish Singh, Keith Black and John Wu, J Clin Oncol 28:7s, 2010 (suppl; abstr 2097). To be presented at the 2010 ASCO Annual Meeting, June 06, 2010.

Related news releases:

ImmunoCellular Therapeutics Ltd. (IMUC) to Present Cancer Vaccine Candidate, International Business Times, June 02, 2010. Excerpt:

Data from the company’s recent clinical trial of ICT-107, the company’s dendritic cell-based cancer vaccine candidate, will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) June 4-8 in Chicago.

See also: Immunocellular brain cancer vaccine shows promise, Reuters, June 02, 2010. Excerpt:

"We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr. John Yu, director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles and ImmunoCellular's chief scientific officer.

Another related news release: Immunocellular Therapeutics Enters into Research Agreement with University of Pennsylvania to Support Phase II Clinical Trial of ICT-107, Business Wire, April 21, 2010.

To Read More: Phase I clinical trial of ICT-107
categoriaStem Cell Therapy commentoComments Off on Phase I clinical trial of ICT-107 | dataJune 3rd, 2010
Read All

When will biotechnology in India be properly regulated? – Daily News & Analysis

By Dr. Matthew Watson


The Hindu
When will biotechnology in India be properly regulated?
Daily News & Analysis
Bangalore: Who regulates research in biotechnology in India? Who takes care of discrepancies in drug pricing, genetic engineering in plants, or the safety ...
BT sector to grow 20%Business Standard
Biotech sector set to grow 20% to $5 bnLivemint
BT sector to become $5 bn industry soonExpress Buzz
Financial Express -mydigitalfc.com -Business Wire India (press release)
all 45 news articles »

To Read More: When will biotechnology in India be properly regulated? – Daily News & Analysis
categoriaUncategorized commentoComments Off on When will biotechnology in India be properly regulated? – Daily News & Analysis | dataJune 3rd, 2010
Read All

Life Technologies Spending $100 Million In Synthetic Biology – Forbes (blog)

By Dr. Matthew Watson


Forbes (blog)
Life Technologies Spending $100 Million In Synthetic Biology
Forbes (blog)
... says it will spend $100 million this year on the nascent field of synthetic biology, the pumped up form of genetic engineering involving multiple genes. ...
Life Technologies Invests In Craig VenterForbes (blog)
Say Hello To Life In The LabTimes of India

all 30 news articles »

To Read More: Life Technologies Spending $100 Million In Synthetic Biology – Forbes (blog)
categoriaUncategorized commentoComments Off on Life Technologies Spending $100 Million In Synthetic Biology – Forbes (blog) | dataJune 2nd, 2010
Read All

Vincenzo Natali explains why Splice is not an anti-science film – io9

By Dr. Matthew Watson


Reuters India
Vincenzo Natali explains why Splice is not an anti-science film
io9
Splice, opening Friday, deals with the abuse of science and the ways in which genetic engineering could go horribly wrong. But it's not an anti-science film ...
Poor Splice In A StorylineSee Magazine
REALLY Weird ScienceCleveland Scene Weekly
Splice Internet TrailerLatino Review
Mania -AHN | All Headline News -San Francisco Chronicle
all 149 news articles »

To Read More: Vincenzo Natali explains why Splice is not an anti-science film – io9
categoriaUncategorized commentoComments Off on Vincenzo Natali explains why Splice is not an anti-science film – io9 | dataJune 2nd, 2010
Read All

Page 613«..1020..612613614615..»